BALCOLTRA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6716814 | AVION PHARMS | Enhancing solubility of iron amino acid chelates and iron proteinates |
Aug, 2021
(2 years ago) | |
| US7838042 | AVION PHARMS | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions |
Jun, 2027
(3 years from now) | |
Balcoltra is owned by Avion Pharms.
Balcoltra contains Ethinyl Estradiol; Levonorgestrel.
Balcoltra has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Balcoltra are:
- US6716814
Balcoltra was authorised for market use on 09 January, 2018.
Balcoltra is available in tablet;oral dosage forms.
Balcoltra can be used as administration of ferrous bisglycinate tablets.
The generics of Balcoltra are possible to be released after 01 June, 2027.
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 09 January, 2018
Treatment: Administration of ferrous bisglycinate tablets
Dosage: TABLET;ORAL
How can I launch a generic of BALCOLTRA before it's drug patent expiration?
More Information on Dosage
BALCOLTRA family patents
